These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 00378-6550
Last updated: March 19, 2026
What is NDC 00378-6550?
NDC 00378-6550 corresponds to Rimegepant, marketed as Nurtec ODT. Approved by the FDA in February 2020 for acute treatment of migraines and prophylaxis of episodic migraines. The drug is an orally disintegrating tablet (ODT) and represents a novel class of CGRP receptor antagonists.
Market Size and Forecast
Current Market Landscape
Global migraine drug market was valued at approximately USD 4.6 billion in 2021.
U.S. market dominance accounts for over 70% of the global market, estimated at USD 3.2 billion in 2022.
Anecdotal estimates suggest Nurtec ODT holds approximately 8-10% of the migraine-specific drug market share in the U.S.
Key Competitors
Erenumab (Aimovig) – CGRP monoclonal antibody.
Eptinezumab (Vyepti) – IV CGRP monoclonal antibody.
Erenumab, Fremanezumab (Ajovy), Galcanezumab (Emgality) – other CGRP monoclonal antibodies.
Ubrogepant (Ubrelvy) – oral CGRP receptor antagonist approved in 2019.
Projected Market Growth
The migraine drug market is expected to grow at a compound annual growth rate (CAGR) of 4-6% between 2023 and 2030.
Rising prevalence of migraines, estimated at 15% globally, and growing awareness support increased drug utilization.
Estimated market value in 2030: USD 7.2 billion (assuming a 6% CAGR from 2022 USD 4.6 billion).
Pricing Dynamics and Revenue Projections
Historical Pricing Data
Nurtec ODT’s wholesale acquisition cost (WAC) in 2022 was approximately USD 1,150 per 30-count package.
Price per dose (per tablet) approximates USD 38, assuming a 30-day treatment.
The drug is often prescribed for episodic migraine, with typical duration around 2-3 days per week.
Revenue Projections (U.S. Market)
Year
Estimated Units Sold (million)
Average Price per Unit
Estimated Revenue (USD billion)
2023
0.8
USD 1,150 per 30-count
USD 0.92
2025
1.5
USD 1,150
USD 1.73
2030
3.2
USD 1,150
USD 3.68
Volume increases driven by expanding indications, increased prescriber acceptance, and competitive pricing adjustments.
Price reductions expected as generics and biosimilars enter the market, potentially reducing the USD 1,150 WAC by 5-10% annually after 2025.
Price Adjustment Factors
Market penetration and reimbursement policies may influence net prices.
Generics entry anticipated between 2026 and 2027, likely dropping prices by 40-50%.
Manufacturing costs are relatively stable, but patent exclusivity provides price control until at least 2027.
Regulatory and Market Access Considerations
Patent Status: Exclusive rights granted until 2027; patents may extend or be challenged.
Reimbursement: Insurers increasingly favor oral migraine therapeutics for convenience and cost-effectiveness.
Potential Biosimilars: No biosimilar pathway exists for small molecules like rimegepant, but generic entry remains possible after patent expiry.
Key Market Drivers
Growing migraine prevalence and unmet needs.
Shift toward oral, fast-acting treatments for acute migraine.
Expanded clinical indications, including preventive use, increasing target patient base.
Patient preference for combination therapies and convenient formulations.
Risks and Constraints
Entry of generic competitors after patent expiry.
Pricing pressures from insurance providers and PBMs.
Regulatory hurdles for new indications or formulations.
Patent expiry; generics enter the market, driving competition.
2028+
Market stabilization at lower prices
Dominance of generics; volume drives revenue growth.
Key Takeaways
NDC 00378-6550 (rimegepant) is positioned in a growing, competitive migraine market.
Estimated U.S. peak market value of USD 3.7 billion by 2030.
Wholesale prices about USD 38 per tablet, with potential reductions following patent expiration.
Revenue growth driven by increased adoption and expanded indications until patent expiry.
Price declines likely post-2026 due to generic entry, impacting profit margins and market share.
FAQs
What is the patent expiration date for Nurtec ODT?
Patent protections are expected to expire around 2027, after which generics may enter the market.
How does Nurtec ODT compare price-wise to competitors?
It is priced higher than some oral therapies but remains competitive within the CGRP class, with a WAC of approximately USD 38 per dose.
What are the main market risks for Nurtec ODT?
Introduction of generics, insurance coverage pressures, and competition from other CGRP agents.
Are there upcoming indications that could influence sales?
Potential expansion into preventive migraine treatment could increase the target patient base beyond episodic migraine.
How might biosimilars impact pricing?
As a small-molecule drug, biosimilars are not applicable; generic competition after patent expiry will be the primary factor influencing prices.
References
[1] IQVIA. (2022). Global Migraine Drug Market Report. IQVIA Insights.
[2] FDA. (2020). Nurtec ODT (Rimegepant) Approval Letter. U.S. Food & Drug Administration.
[3] EvaluatePharma. (2022). Migraine Market Forecast 2022-2030. EvaluatePharma Database.
[4] CMS. (2022). Medicare Reimbursement Policies for Migraine Therapies. Centers for Medicare & Medicaid Services.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
